You won’t find info on this early-stage biotech startup anywhere else…
One hundred years ago, soon-to-be pharmaceutical giants Upjohn – which became a part of Pfizer, now worth well over $200 billion – and Eli Lilly were mass cultivating cannabis in the United States for medical purposes.
Of course, cannabis prohibition put a halt to this research for decades.
But a team of pharmaceutical industry vets, headed up by a world-renowned physician who helped take the cannabis as medicine movement mainstream, is picking up right where these companies left off to bring 27 unique and highly profitable cannabis-based treatments to market.
Each of these revolutionary treatments could end up being worth more than $1 billion upon Food and Drug Administration (FDA) approval, which could grow their $40 million startup to a $21.6 billion behemoth in just a few short years.
Now, this startup is coming out of stealth mode for the first time ever this Wednesday, September 2 at 1:00 P.M. in an exclusive National Institute for Cannabis Investors virtual event.
Meet the Early-Stage Biotech Startup Reinventing Cannabis-Based Medicine
For the past 11 years, this startup’s founder – a well-known Harvard-trained doctor – has risked everything to help patients who have nowhere else to turn with cannabis-based medicine. During that time, he put together an unprecedented 25,000-patient gold mine of data.
And with the help of an all-star team of pharmaceutical experts, he’s turning that gold mine of data into cannabis-based drugs that could completely transform the pharmaceutical landscape.
I’ve had the pleasure of working with this team for the past several months to bring you this rare opportunity and I can’t wait to reveal their plans for the first time ever.
It’s all going down this Wednesday, September 2 at 1:00 P.M.
Executive Director, National Institute for Cannabis Investors
August 31 2020